CHICAGO--(BUSINESS WIRE)--If You Purchased, Paid for, or Provided Reimbursement for the Alzheimer’s Disease Drug Namenda XR or Namenda IR and its AB-rated generic equivalents, between April 14, 2010 through December 31, 2017 (the estimated date that the anticompetitive effects of Generic Defendants’ unlawful conduct...